ReviewVirulence2022
Pathogenicity and virulence of Marburg virus.
Review in Virulence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Re-emerging Marburg virus disease in Africa: spillover ecology, geographic expansion, and surveillance vulnerabilities.Emerging microbes & infections · 2026Review
- Marburg virus persistence and clinical complications among recovered persons in Rwanda: a longitudinal study protocol.BMJ open · 2026Article
- Marburg Virus Glycoprotein Is a Remarkable Virulent Factor Linked to Hemorrhagic Pathology: Evidence from Multimodal Experimental Systems.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- MARVpred: machine learning prediction of inhibitors targeting Marburg virus Gene 4 Small ORF protein.BMC infectious diseases · 2026Article
- Effect of the AHR Inhibitor CH223191 as an Adjunct Treatment for Mammarenavirus Infections.International journal of molecular sciences · 2026Article
- Assessment of healthcare worker preparedness and health literacy for Marburg virus disease in Nigeria: A cross-sectional study.Southern African journal of infectious diseases · 2026Article
- A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease.Emerging microbes & infections · 2025Article
- Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine.The Journal of general virology · 2025Article
- Integrated computational approach revealed the potential inhibitory effect of xanthone derivatives against Marburg virus nucleocapsid.Virusdisease · 2025Article
- Marburg virus disease: Emerging threat, pathogenesis, and global public health strategies.World journal of virology · 2025Review
- Marburg virus outbreak: a global health threat, zoonotic risks, and the urgent need for international action.Virusdisease · 2025Article
- Review
- Outbreak of Marburg Virus Disease, Equatorial Guinea, 2023.Emerging infectious diseases · 2025Review
- Therapeutic advances in Marburg virus disease: from experimental treatments to vaccine development.Annals of medicine and surgery (2012) · 2025Review
- Marburg Virus Disease: A Narrative Review.Health science reports · 2025Article
- Safeguarding global health security amidst a scramble for Africa's minerals for the clean energy transition.Globalization and health · 2025Article
- Immunogenicity, Pathogenesis, and Host's Immuno-Responses to Marburg Virus Infection.Pathogens (Basel, Switzerland) · 2025Review
- Genomic and transmission dynamics of the 2024 Marburg virus outbreak in Rwanda.Nature medicine · 2025Article
- Reporter-expressing viruses for antiviral drug discovery research.Frontiers in cellular and infection microbiology · 2025Review
- Ebola and Marburg viruses IgG detections in small ruminants and dogs from villages within outbreak areas in Gabon.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marburg virus (MARV) has been a major concern since 1967, with two major outbreaks occurring in 1998 and 2004. Infection from MARV results in severe hemorrhagic fever, causing organ dysfunction and death. Exposure to fruit bats in caves and mines, and human-to-human transmission had major roles in the amplification of MARV outbreaks in African countries. The high fatality rate of up to 90% demands the broad study of MARV diseases (MVD) that correspond with MARV infection. Since large outbreaks are rare for MARV, clinical investigations are often inadequate for providing the substantial data necessary to determine the treatment of MARV disease. Therefore, an overall review may contribute to minimizing the limitations associated with future medical research and improve the clinical management of MVD. In this review, we sought to analyze and amalgamate significant information regarding MARV disease epidemics, pathophysiology, and management approaches to provide a better understanding of this deadly virus and the associated infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.